v3.26.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2026
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

Cost of revenue

 

$

380

 

 

$

300

 

Research, development and clinical trials
 expenses

 

 

1,470

 

 

 

1,316

 

Selling, general and administrative expenses

 

 

8,102

 

 

 

7,342

 

 

 

$

9,952

 

 

$

8,958